Follow-The-Filings

Security · featured owners

STOK Stoke Therapeutics Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 3 Owners
  • Max 2.1%
  • $30M
  • 1 exit

STOK (Stoke Therapeutics Inc.) is held in 3 featured 13F books as of 2026 Q2. James Silverman - Opaleye Management is the largest tracked holder by portfolio weight (2.1%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 2.1% (James Silverman - Opaleye Management) · not free-float ownership

  1. James Silverman 2.1%
  2. Nathan Fischel 0.82%
  3. Palo Alto Investors 0.38%

Holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

History
James Silverman - Opaleye Management 2026 Q2 2.1% Hold 700,000 $23M History
Nathan Fischel - Dafna Capital Management 2026 Q2 0.82% Hold 130,875 $4M History
Palo Alto Investors 2026 Q2 0.38% Hold 84,631 $3M History
Farallon Capital Management exited 2026 Q2 Last 2026 Q1 <0.01% Exit 0.00% 9,000 $293K History

3 current · 1 exited last period · options excluded

SEC filings

Recent issuer filings from EDGAR · 12 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 5.02 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 5.07 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEFA14A Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 4.01,9.01 Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 15 rows shown

Filed Form Detail Links
4 Period Sep 23, 2026 Filing Doc
4 Period Sep 1, 2026 Filing Doc
4 Period Aug 14, 2026 · 3 forms Filing Doc
4 Period Aug 3, 2026 Filing Doc
4 Period Jul 15, 2026 Filing Doc
4 Period Jul 16, 2026 Filing Doc
4 Period Jul 1, 2026 Filing Doc
4 Period Jun 16, 2026 Filing Doc
4 Period Jun 3, 2026 · 7 forms Filing Doc
4 Period Jun 1, 2026 Filing Doc
4 Period May 1, 2026 Filing Doc
4 Period Apr 3, 2026 Filing Doc
4 Period Apr 1, 2026 Filing Doc
4 Period Mar 20, 2026 Filing Doc
4 Period Mar 17, 2026 · 3 forms Filing Doc

Updated 4 days ago Source: SEC EDGAR submissions All on EDGAR

Financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $8.78M $36.56M $184.42M
Net income -$104.7M -$88.98M -$6.88M
Net margin * -1192.5% -243.4% -3.7%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $215.34M $232.76M $305.7M
Total non-current assets * $13M $38.8M $112.73M
Total assets $228.34M $271.56M $418.43M
Total current liabilities $30.82M $40.06M $57.88M
Total non-current liabilities $37.96M $2.48M $8.1M
Total equity $159.56M $229.02M $352.46M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$81.07M -$86.85M $45.58M
Cash from investing $105.95M -$107.48M -$186.81M
Cash from financing $53.01M $131.09M $97.39M
Net change in cash $77.89M -$63.23M -$43.84M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

Ownership over time

filing count by report period · click a bar for that quarter’s holders